Significant step towards Alvogen's ambition to be a top-5 business in (APAC)
Third significant acquisition in region since 2012, highlighting Alvogen's role as leading regional industry consolidator
PINEBROOK, N.J.--(BUSINESS WIRE)--Alvogen, the international pharmaceuticals company announced today that it has acquired Dream Pharma ("Dream") in South Korea for US$ 187 million in cash. Dream will be acquired through Alvogen's Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea. The transaction represents a significant milestone in Alvogen's stated ambition to become one of the top five regional players in the APAC market.
The acquisition of Dream will significantly strengthen Alvogen's existing business in South Korea, adding a complementary portfolio of over 100 products. Dream currently has an impressive 35% market share in obesity products in Korea, with no overlap with 's current portfolio in the market. The consolidated business creates a strong platform for exports and a basis upon which to introduce the Korean portfolio into other APAC markets.
Alvogen's acquisition of Dream is the third significant acquisition that the Group has made in APAC since 2012. The transaction will create a strong platform from which Alvogen can drive revenue and profit growth across the region. APAC is one of the fastest-growing regions globally for generic pharmaceuticals. The market remains very fragmented, which provides an excellent opportunity for Alvogen to play a leading role in further industry consolidation, with a focus on building a selective, hiqh quality product portfolio in markets such as Korea, , , , and
Third significant acquisition in region since 2012, highlighting Alvogen's role as leading regional industry consolidator
PINEBROOK, N.J.--(BUSINESS WIRE)--Alvogen, the international pharmaceuticals company announced today that it has acquired Dream Pharma ("Dream") in South Korea for US$ 187 million in cash. Dream will be acquired through Alvogen's Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea. The transaction represents a significant milestone in Alvogen's stated ambition to become one of the top five regional players in the APAC market.
The acquisition of Dream will significantly strengthen Alvogen's existing business in South Korea, adding a complementary portfolio of over 100 products. Dream currently has an impressive 35% market share in obesity products in Korea, with no overlap with 's current portfolio in the market. The consolidated business creates a strong platform for exports and a basis upon which to introduce the Korean portfolio into other APAC markets.
Alvogen's acquisition of Dream is the third significant acquisition that the Group has made in APAC since 2012. The transaction will create a strong platform from which Alvogen can drive revenue and profit growth across the region. APAC is one of the fastest-growing regions globally for generic pharmaceuticals. The market remains very fragmented, which provides an excellent opportunity for Alvogen to play a leading role in further industry consolidation, with a focus on building a selective, hiqh quality product portfolio in markets such as Korea, , , , and
No comments:
Post a Comment